Safety Study of Recombinant Vaccinia Virus Administered Intravenously in Patients With Metastatic, Refractory Colorectal Carcinoma

Carcinoma, Colorectal Clinical Trial

Official title:
A Phase 1b Dose Escalation Study of JX-594 (Thymidine Kinase-Inactivated Vaccinia Virus Plus GM-CSF) Administered by Biweekly (Every Two Weeks) Intravenous Infusion in Patients With Metastatic, Refractory Colorectal Carcinoma

Status Completed

Clinical Trial Summary

The purpose of this pilot safety study is to evaluate the safety and tolerability of JX-594 (Pexa-Vec) administered intravenously every 2 weeks in colorectal carcinoma patients who are refractory to or intolerant of oxaliplatin, irinotecan, and Erbitux treatments.

Clinical Trial Description

n/a

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01380600
Study type	Interventional
Source	SillaJen, Inc.
Contact
Status	Completed
Phase	Phase 1
Start date	July 2010
Completion date	December 2015

View Details

See also
	Status	Clinical Trial	Phase
	Recruiting	`NCT04291755` - Development and Analysis of a Stool Bank for Cancer Patients
	Recruiting	`NCT04699188` - Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation	Phase 1/Phase 2